Table 2.

Summary of biomarker levels at pre-RT and after completion of RT in breast cancer and lung cancer/lymphoma

	Breast cancer			Lung cancer/Mediastinal lymphoma
Biomarker	Pre-RT	Post-RT	P value	Pre-RT	Post-RT	P value
hs-cTnT, ng/L	11 [6–23]	8 [5–13]	<.001	11 [8–18]	9 [6–16]	.057
NT-proBNP, ng/L	77 [42–118]	76 [40–139]	.430	70 [25–114]	64 [38–168]	.860
PIGF, ng/L	18 [15–23]	19 [13–24]	.746	20 [16–26]	22 [16–30]	.005
GDF-15, ng/L	1012 [676–1513]	1093 [841–1505]	.054	1171 [755–2493]	1887 [903–3763]	.006

Abbreviations: GDF-15 = growth differentiation factor 15; hs-cTnT = high-sensitivity cardiac troponin T; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PIGF = placental growth factor; RT = radiation therapy.

Median (interquartile range) was used to summarize biomarker levels. Differences in biomarker levels at the 2 time points were statistically tested with the Wilcoxon signed-rank test.